ユタにおけるリンパ腫の臨床試験
ユタ内の拠点で、リンパ腫に関する14件の研究が参加者を募集しています。
ユタ内の都市
公式研究テキスト（英語）
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Intermountain Health, Canyons Region, LDS Hospital, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06343311A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
- Huntsman Cancer Institute, Salt Lake City
被験者募集中
18歳以上 · 全性別 · 2026/09/28更新 · NCT07013435A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Utah, Salt Lake City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07221500CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Primary Children's Hospital, Salt Lake City
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/09/11更新 · NCT04870944Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- START Mountain Region, West Valley City
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/08/20更新 · NCT06678659A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Intermountain Healthcare, Salt Lake City
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Huntsman Cancer Institute, University of Utah, Salt Lake City
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/01更新 · NCT05663502Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
- START Mountain Region, West Valley City
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/04更新 · NCT06132503Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
- START Mountain Region, West Valley City
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/24更新 · NCT06801002CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Huntsman Cancer Institute, University of Utah, Salt Lake City
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
- Huntsman Cancer Institute at University of Utah, Salt Lake City
被験者募集中
21歳以上 · 全性別 · 2026/02/05更新 · NCT07390071A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Utah, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/14更新 · NCT05643742ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。